Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
Conditions
Interventions
hAd5-S-Fusion+N-ETSD
Placebo (0.9% (w/v) saline)
Locations
1
United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Start Date
December 9, 2020
Primary Completion Date
June 23, 2022
Completion Date
July 19, 2023
Last Updated
June 7, 2024
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT07221162
Lead Sponsor
ImmunityBio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions